Abstract: The present application provides compositions and methods for preparing and using “heavy” nucleotide derivatives of thymidine or uridine by replacing the oxygen atom attached to one or more of positions with non-radioactive oxygen-18 (18O), administering it to a subject to target a tumor including incorporation into tumor cell DNA, and then treating the tumor with proton beam therapy to transmutate the 18O to 18F, resulting in a break of the new fluorine-phosphorous bond. This chemical event destabilizes ribose-phosphate DNA back-bone and base pairing thus produce single- and double strand breaks, clusters lesions that can lead to irreparable DNA damage and enhanced tumor cell killing. The atomic, chemical, and physical aspects result in the use of lower radiation doses and significantly alter acute and late morbidity of radiotherapy. Heavy thymidine and heavy uridine derivatives labeled with 18O have been made and tested.

Abstract: Methods, systems, and computer readable media for utilizing a therapeutic ultrasound device to perform mitral valve decalcification are disclosed. One method includes acquiring, via an ultrasound imaging component, imaging data of a mitral valve in real-time, defining a therapeutic region of interest corresponding to the mitral valve, and utilizing, by a system controller engine, imaging data from the ultrasound imaging component to determine an interval period of minimal mitral annular movement.

Abstract: The present invention provides for a composition comprising a purified or isolated Hyde1 gene product, or a functional fragment thereof; a modified host cell capable of expressing a Type VI secretion system (T6SS), Hyde1, and/or Hyde2, or a functional fragment thereof; a method of treating a disease caused all or in part by a bacterial cell, comprising administering a composition of the present invention to a subject in need thereof; and a method to limit or reduce growth of a pathogenic bacteria in an environment, comprising: introducing a non-pathogenic bacterial capable of expressing a Type VI secretion system (T6SS), Hyde1, and/or Hyde2, or functional fragment thereof, to an environment.

Abstract: A method of synthesis of metal organic frameworks (“MOFs”) includes preparing a metal solution by dissolving at least one metal salt in an aqueous solution and buffering the metal solution with a base to achieve a first pH, the metal solution optionally comprising an organic co-solvent, preparing a linker solution by adding at least one organic acid linker and at least one base to an aqueous solution, and mixing the metal solution and the linker solution to produce the MOFs. The at least one organic acid linker has an ability to be protonated or deprotonated in response to a second pH, and the mixture of the metal solution and the linker solution has a third pH value, where the third pH value is greater than a highest pKa of the organic acid linker. The MOFs may be applied to a textile.

Abstract: A pharmaceutical composition and methods for using the pharmaceutical composition are disclosed. The pharmaceutical composition may include a therapeutically effective amount of one or more antiviral active pharmaceutical ingredients and a pharmaceutically acceptable excipient. The pharmaceutical composition may be a solid dosage form, wherein the solid dosage form provides sustained release of the antiviral active pharmaceutical ingredient when administered as a vaginal or rectal insert.

Abstract: Sulfonyl-triazole compounds and related sulfonyl-heterocycle compounds are described. The compounds can be used to identify reactive nucleophilic amino acid residues, such as reactive tyrosines and reactive lysines, in proteins and to modify the activity of proteins with reactive nucleophilic amino acid residues via the formation of protein adducts comprising a fragment of the compounds. Methods are also described for screening the compounds to identify ligands of proteins comprising a reactive lysine or a reactive tyrosine.

Abstract: A method of improving a neurodegenerative or cognitive disorder in a human patient suffering therefrom is provided by determining a target site of the human patient's brain that is affected by the neurodegenerative disorder or cognitive disorder and providing a therapy to the human patient. The therapy includes applying a low intensity focused ultrasound (LiFUS) sonication via an ultrasound delivery device to the target site based on an imaging parameter, a microbubble cavitation; an optical parameter, a bodily fluid parameter, or a physiological or anatomical parameter of the human patient's brain. A therapeutic agent is introduced to the target site before, after or during application of the LiFUS sonication.

Abstract: Disclosed are compositions and methods for treating a disease or disorder such as cancer in a subject in need thereof. In some embodiments, the methods include administering to the subject a vector that has a first nucleic acid sequence encoding a promoter operably linked to each of a second nucleic acid sequence encoding a therapeutic polypeptide, and a third nucleic acid sequence encoding a peptide domain that is stabilized when phosphorylated by kinase activity in a target cell and/or tissue. In some embodiments, the target cell and/or tissue can be a cell and/or tissue undergoing a stress response. In some embodiments, the target cell and/or tissue can be a cell and/or tissue in which a CK2 kinase is active. The kinase activity can be elevated extracellular regulated kinase (ERK) activity, p38 MAP kinase activity, and/or CK2 activity.

Abstract: Method, system and computer program product for providing real time detection of analyte sensor sensitivity decline is continuous glucose monitoring systems are provided.

Abstract: Antipathogenic polypeptides and related compounds and compositions that display antipathogenic activity, antifungal activity (i.e., act as fungicides), antialgal activity (i.e., act as algaecides), and/or enzymatic activity against chitin (i.e., degrade chitin) and/or polyglucuronic acid (i.e., degrade the polyglucuronic acid) are described. These antipathogenic polypeptides, as well the related compounds and compositions disclosed herein, can be used in protecting/treating products, including but not limited to agricultural products and water bodies (including drinking water), from pathogens, including fungi and algae, as well as generating pathogen-resistant products (particularly fungi-resistant and/or algae-resistant products).

Abstract: Provided is a method of data storage, the method including receiving, at a host of a key-value store, a request to access a data node stored on a storage device of the key-value store, locating an address corresponding to the data node in a host cache on the host, and determining that the data node is in a kernel cache on the storage device.

Abstract: A method of making an article comprising one or more layers of plasmonic nanoparticles located between opposing layers of dielectric materials and an article comprising one or more layers of plasmonic nanoparticles located between opposing layers of dielectric materials.

Abstract: Described herein are engineered hemichannels, engineered vesicles that can contain the one or more of the engineered hemichannels, pharmaceutical formulations thereof, and uses thereof. In some aspects, the engineered vesicles can include one or more cargo molecules. Also described herein are methods of loading the engineered vesicles. In some aspects, loading of one or more cargo molecules engineered vesicles can be optionally via an engineered hemichannel contained in the engineered vesicle.

Abstract: A system and method for monitoring the health of dialysis patients with Raman spectroscopy measurements of one or more target analytes is described. The methods include irradiating one or more fluids of interest with light to produce one or more spectrum and detecting the spectrum with a detector. The fluids of interest are preferably those related to dialysis, including hemodialysis and peritoneal dialysis. In a preferred embodiment, the fluids are irradiated with monochromatic light, and one or more Raman spectra are detected as a result of the irradiation. The fluids may be irradiated within the dialysis tubing itself, or removed from the dialysis tubing and irradiated in a separate chamber. The Raman spectra of one or more target analytes of a dialysis patient may be followed over time or compared to one or more reference spectra, thereby providing information on the health of dialysis patients.

Abstract: In some embodiments herein, methods, compositions, and uses for countering the effects of aberrant meningeal lymphatic drainage and/or modulating lymphatic vessels of the central nervous system are described. In some embodiments, methods, compositions, or uses for treating, preventing, or ameliorating symptoms of a neurodegenerative disease associated with aberrant meningeal lymphatic drainage are described. Modulating lymphatic vessels, or countering the effects of aberrant meningeal lymphatic drainage, in accordance with some embodiments, are used to diagnose, treat, prevent, or ameliorate symptoms of neurodegenerative diseases such as Alzheimer's disease (AD) and dementia. Methods of diagnosing and monitoring the progression of neurological diseases are also provided.

Abstract: The present disclosure relates to compositions and methods related to tissue-specific promoters and their uses in plants, including tobacco and cannabis. The provided trichome-specific promoters enable the expression of heterologous polynucleotides in trichome tissues.

Abstract: Compositions and methods for genetically modifying the production levels of nicotine and other alkaloids in plants are provided.

Abstract: The present invention provides novel antibodies and antigen binding fragments thereof that bind to human CD30. Also presented are single chain variable antibodies, chimeric antigen receptors and uses thereof. Methods of treating cancer are also disclosed.

Abstract: An article may include a substrate and a coating system on the substrate. The coating system may include a thermal and/or environmental barrier coating (T/EBC) layer, wherein the T/EBC layer includes a silicate phase including more than one metal cation.

Abstract: A method for resuscitation of the heart in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a solution comprising polyethylene glycol (PEG) having a molecular weight of 8-100 kDa is provided.